DUBLIN, March 12, 2024 /PRNewswire/ — The “Global Immune Thrombocytopenia Drug Market (2024 Edition): Analysis By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type, By End-User, By Region: Market Insights and Forecast (2019-2029)” report has been added to ResearchAndMarkets.com’s offering.
The Global Immune Thrombocytopenia Drug market showcased growth at a CAGR of 21.32% during 2019-2022. The market was valued at USD 3661.45 Million in 2022 which is expected to reach USD 12308.37 Million in 2029.
Immune Thrombocytopenia Drug Market is being propelled by rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.
According to National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years, The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in research and development, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition.
Also, According to National Organization of Rare Disease, In the United States, the annual incidence of ITP is estimated around 3.3 per 100,000 people.3 In Europe, the annual incidence of ITP among adults is estimated at around 1 to 4 per 100,000 people. The growing prevalence of ITP in the has stimulated research and development efforts in the field of ITP drugs. Pharmaceutical companies in these regions have responded to the growing demand for ITP treatments by developing and marketing drugs to address the needs of patients with this condition across different geographic areas.
Novel drug delivery technologies have enhanced the administration and effectiveness of ITP medications. Long-acting formulations, subcutaneous injections, and oral formulations offer improved convenience, reduced dosing frequency, and enhanced patient adherence compared to traditional intravenous therapies. These advancements in drug delivery technology have improved patient comfort and treatment compliance in ITP management.
Advancements in TPO-RAs have led to the development of new agents with improved efficacy and safety profiles. Second-generation TPO-RAs, such as avatrombopag and lusutrombopag, have demonstrated superior platelet response rates and reduced side effects compared to earlier agents like romiplostim and eltrombopag. These advancements have expanded treatment options for patients with ITP and improved treatment outcomes.
Hospitals and clinics have adopted advanced diagnostic technologies to facilitate accurate and timely diagnosis of ITP. Techniques such as flow cytometry, polymerase chain reaction (PCR), and genetic testing allow for the detection of immune dysregulation, autoantibodies, and underlying genetic predispositions in patients with ITP. Advanced diagnostic technologies enable healthcare providers to differentiate primary ITP from secondary causes of thrombocytopenia, guiding treatment decisions and improving patient outcomes.
Technological advancements drive innovation and progress in the global Immune Thrombocytopenia Drug Market, accelerating drug discovery, development, manufacturing, and clinical practice. These advancements enhance biomarker discovery, high-throughput screening, computational modeling, biopharmaceutical manufacturing, drug delivery systems, and digital health technologies, improving the efficacy, safety, and accessibility of ITP treatments for patients worldwide.
Scope of the Report
The report analyses the Immune Thrombocytopenia Drug Market by Value (USD Million).
The report analyses the Immune Thrombocytopenia Drug Market by Pipeline Scenario.
The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India).
The report presents the analysis of Immune Thrombocytopenia Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the Immune Thrombocytopenia Drug Market by Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others).
The report analyses the Immune Thrombocytopenia Drug Market by End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes).
The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By treatment, by type & by end users.
Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
Analyst Recommendations
Amplify development of intravenous drugs for chronic application
Escalate collaboration initiative with healthcare provider
Competitive Positioning
CSL Behring
Rigel Pharmaceuticals
Novartis
Pfizer
Teva Pharmaceutical
Sanofi
Amgen, Inc.
Grifols
Takeda Pharmaceuticals
Intas Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/cw2bwq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets